Physician profile
Maya Balakrishnan
NPI 1295911584
$10,612.76
in general payments reported to CMS, 2019-2025
12 companies · $3,231 in 2025
The $3,231 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $4,551 · 2021: $44.85 · 2023: $2,713 · 2024: $72.91 · 2025: $3,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,533 · Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,532.50 |
| Food and Beverage | $484.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $4,551.31 | 2020 | |
| Madrigal Pharmaceuticals | $3,119.01 | 2025 | Rezdiffra |
| Novo Nordisk INC | $2,757.35 | 2021-2023 | |
| Gilead Sciences, INC. | $50.80 | 2025 | |
| Albireo Pharma, INC. | $44.28 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $28.63 | 2024 | Entyvio |
| Janssen Biotech, INC. | $23.83 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $19.62 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.93 | 2025 | Xifaxan |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Balakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.